Inovio Pharmaceuticals Stock Today
| INO Stock | USD 2.15 0.02 0.94% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Inovio Pharmaceuticals is selling at 2.15 as of the 16th of February 2025; that is 0.94 percent increase since the beginning of the trading day. The stock's open price was 2.13. Inovio Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of February 1998 | Category Healthcare | Classification Health Care |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus , cancer, and infectious diseases. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. The company has 36.1 M outstanding shares of which 5.01 M shares are currently shorted by investors with about 4.4 days to cover. More on Inovio Pharmaceuticals
Moving together with Inovio Stock
Moving against Inovio Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Inovio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Jacqueline Shea | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Inseego Corp, Inseego Corp] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Aggressive Defence, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInovio Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inovio Pharmaceuticals' financial leverage. It provides some insight into what part of Inovio Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inovio Pharmaceuticals (INO) is traded on NASDAQ Exchange in USA. It is located in 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 and employs 127 people. Inovio Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 77.61 M. Inovio Pharmaceuticals runs under Biotechnology sector within Health Care industry. The entity has 36.1 M outstanding shares of which 5.01 M shares are currently shorted by investors with about 4.4 days to cover.
Inovio Pharmaceuticals has about 348.13 M in cash with (124.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4.
Check Inovio Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationInovio Pharmaceuticals has a total of 36.1 Million outstanding shares. 30% of Inovio Pharmaceuticals outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Inovio Ownership Details
Inovio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Deerfield Management Co | 2024-09-30 | 76.5 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 73.2 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 71.1 K | |
| Wellington Management Company Llp | 2024-09-30 | 65.6 K | |
| Green Alpha Advisors, Llc | 2024-12-31 | 65.4 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 61.6 K | |
| Bank Of America Corp | 2024-09-30 | 56.5 K | |
| Squarepoint Ops Llc | 2024-09-30 | 51.5 K | |
| Nuveen Asset Management, Llc | 2024-09-30 | 46.5 K | |
| Blackrock Inc | 2024-09-30 | 1.9 M | |
| Deep Track Capital, Lp | 2024-09-30 | 1.8 M |
Inovio Pharmaceuticals Historical Income Statement
Inovio Stock Against Markets
Inovio Pharmaceuticals Corporate Management
| Asli Gevgilili | Chief Officer | Profile | |
| Jeffrey Skolnik | Senior Development | Profile | |
| Robert Juba | Senior Management | Profile | |
| E MBA | Senior Assurance | Profile | |
| MBA MA | Senior Development | Profile | |
| Ben Matone | Director Relations | Profile | |
| Laurent Humeau | Chief Scientific Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share | Quarterly Revenue Growth (0.55) | Return On Assets | Return On Equity |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.